Cargando…

Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease

Background  Cognitive deficit in Parkinson disease (PD) is an important cause of functional disability in these patients and early detection, with sensitive instruments, can contribute to longitudinal monitoring. Objective  To investigate the diagnostic accuracy, sensitivity, and specificity of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa, Nariana Mattos Figueiredo, Brucki, Sonia Maria Dozzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033197/
https://www.ncbi.nlm.nih.gov/pubmed/36863401
http://dx.doi.org/10.1055/s-0042-1758448
_version_ 1784910958365245440
author Sousa, Nariana Mattos Figueiredo
Brucki, Sonia Maria Dozzi
author_facet Sousa, Nariana Mattos Figueiredo
Brucki, Sonia Maria Dozzi
author_sort Sousa, Nariana Mattos Figueiredo
collection PubMed
description Background  Cognitive deficit in Parkinson disease (PD) is an important cause of functional disability in these patients and early detection, with sensitive instruments, can contribute to longitudinal monitoring. Objective  To investigate the diagnostic accuracy, sensitivity, and specificity of the Addenbrooke's Cognitive Examination-III in patients with PD, using the comprehensive neuropsychological battery as reference method. Methods  Cross-sectional, observational, case-control study. Setting: rehabilitation service. A total of 150 patients and 60 healthy controls matched for age, sex, and education. For level I assessment, Addenbrooke Cognitive Examination (ACE-III) was used. Level II assessment used a comprehensive neuropsychological battery of standardized tests for this population. All patients remained in on-state during the study. The diagnostic accuracy of the battery was investigated through the receiver operating characteristic (ROC) analysis. Results  The clinical group was divided into 3 subgroups: normal cognition in Parkinson's disease (NC-PD-16%), mild cognitive impairment due to Parkinson's disease (MCI-PD-69.33%), and dementia due to Parkinson's disease (D-PD-14.66%). ACE-III optimal cutoff scores for detecting MCI-PD and D-PD were 85/100 (sensitivity 58.65%, specificity 60%) and 81/100 points (sensitivity 77.27%, specificity 78.33%), respectively. Age was inversely associated with the performance of the scores (totals and domains of the ACE-III), while the level of education had a significantly positive correlation in the performance of these scores. Conclusions  ACE-III is a useful battery for assessing the cognitive domains and to differentiate individuals with MCI-PD and D-PD from healthy controls. Future research, in a community setting, is necessary to provide discriminatory capacity of ACE-III in the different severities of dementia.
format Online
Article
Text
id pubmed-10033197
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Thieme Revinter Publicações Ltda.
record_format MEDLINE/PubMed
spelling pubmed-100331972023-03-23 Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease Sousa, Nariana Mattos Figueiredo Brucki, Sonia Maria Dozzi Arq Neuropsiquiatr Background  Cognitive deficit in Parkinson disease (PD) is an important cause of functional disability in these patients and early detection, with sensitive instruments, can contribute to longitudinal monitoring. Objective  To investigate the diagnostic accuracy, sensitivity, and specificity of the Addenbrooke's Cognitive Examination-III in patients with PD, using the comprehensive neuropsychological battery as reference method. Methods  Cross-sectional, observational, case-control study. Setting: rehabilitation service. A total of 150 patients and 60 healthy controls matched for age, sex, and education. For level I assessment, Addenbrooke Cognitive Examination (ACE-III) was used. Level II assessment used a comprehensive neuropsychological battery of standardized tests for this population. All patients remained in on-state during the study. The diagnostic accuracy of the battery was investigated through the receiver operating characteristic (ROC) analysis. Results  The clinical group was divided into 3 subgroups: normal cognition in Parkinson's disease (NC-PD-16%), mild cognitive impairment due to Parkinson's disease (MCI-PD-69.33%), and dementia due to Parkinson's disease (D-PD-14.66%). ACE-III optimal cutoff scores for detecting MCI-PD and D-PD were 85/100 (sensitivity 58.65%, specificity 60%) and 81/100 points (sensitivity 77.27%, specificity 78.33%), respectively. Age was inversely associated with the performance of the scores (totals and domains of the ACE-III), while the level of education had a significantly positive correlation in the performance of these scores. Conclusions  ACE-III is a useful battery for assessing the cognitive domains and to differentiate individuals with MCI-PD and D-PD from healthy controls. Future research, in a community setting, is necessary to provide discriminatory capacity of ACE-III in the different severities of dementia. Thieme Revinter Publicações Ltda. 2023-03-02 /pmc/articles/PMC10033197/ /pubmed/36863401 http://dx.doi.org/10.1055/s-0042-1758448 Text en Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Sousa, Nariana Mattos Figueiredo
Brucki, Sonia Maria Dozzi
Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease
title Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease
title_full Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease
title_fullStr Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease
title_full_unstemmed Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease
title_short Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease
title_sort addenbrooke's cognitive examination iii: diagnostic utility for detecting mild cognitive impairment and dementia in parkinson's disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033197/
https://www.ncbi.nlm.nih.gov/pubmed/36863401
http://dx.doi.org/10.1055/s-0042-1758448
work_keys_str_mv AT sousanarianamattosfigueiredo addenbrookescognitiveexaminationiiidiagnosticutilityfordetectingmildcognitiveimpairmentanddementiainparkinsonsdisease
AT bruckisoniamariadozzi addenbrookescognitiveexaminationiiidiagnosticutilityfordetectingmildcognitiveimpairmentanddementiainparkinsonsdisease